Celltrion's AVTOZMA® Gains FDA Approval for Multiple Indications
Celltrion has officially announced the U.S. Food and Drug Administration (FDA)'s approval of AVTOZMA® (CT-P47, tocilizumab-anoh), a biosimilar to ACTEMRA®. This significant milestone marks AVTOZMA's availability in both intravenous (IV) and subcutaneous (SC) formulations, providing healthcare professionals with versatile treatment options.
Comprehensive Treatment Options with AVTOZMA®
AVTOZMA® is now authorized for several critical indications: rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), and even COVID-19 infections. This broad range of approvals positions AVTOZMA® as a vital part of treatment regimens across different patient demographics.
Significance of AVTOZMA® in Celltrion's Portfolio
With this approval, AVTOZMA becomes Celltrion's fifth immunology biologic and seventh FDA-approved biosimilar. The strategic introduction of both IV and SC formulations allows for adaptability in treatment. As stated by Thomas Nusbickel, Chief Commercial Officer at Celltrion USA, this launch reflects their commitment to enhancing access to high-quality care for patients.
Clinical Evidence Supporting AVTOZMA's Approval
The FDA's decision stemmed from a robust data package demonstrating AVTOZMA's biosimilarity to reference tocilizumab, particularly noted in a phase III study focused on patients with moderate to severe active rheumatoid arthritis. Results indicated that AVTOZMA met key efficacy endpoints, confirming its comparable effectiveness and safety profile to the original tocilizumab treatment.
Comparison of Formulations
AVTOZMA® will be available in both IV and SC formats with identical formulations and dosages to those of ACTEMRA®. The IV options include 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL, while the SC injection is available in a 162 mg/0.9 mL dose, conveniently packed in single-dose autoinjectors or prefilled syringes.
About AVTOZMA®
As a recombinant humanized monoclonal antibody, AVTOZMA® acts as an IL-6 receptor antagonist. The comprehensive phase III trials aimed at comparing its efficacy, PK, safety, and immunogenicity against reference tocilizumab bolstered its regulatory approval with both the FDA and European Medicines Agency (EMA).
Indications and Important Safety Information
AVTOZMA® is specifically designated for conditions such as:
- Rheumatoid Arthritis (RA): Adult patients showing inadequate responses to DMARDs.
- Giant Cell Arteritis (GCA): Indicated for adults diagnosed with GCA.
- Polyarticular Juvenile Idiopathic Arthritis (pJIA): For patients aged two or older with pJIA.
- Systemic Juvenile Idiopathic Arthritis (sJIA): Similarly for patients aged two or more showing active symptoms.
- COVID-19: For hospitalized adults receiving systemic corticosteroids requiring oxygen supplementation.
AVTOZMA® does carry important safety warnings, such as the risk of serious infections, notably for patients using concurrent immunosuppressants. Regular monitoring and appropriate management are crucial for patient safety.
About Celltrion
Celltrion is a prominent biopharmaceutical enterprise headquartered in Incheon, South Korea. With a strong focus on innovative therapeutics, the company ensures high-quality solutions, serving patients across more than 110 countries. With seven FDA-approved biosimilars to its name, Celltrion is dedicated to improving healthcare accessibility worldwide.
Frequently Asked Questions
What is AVTOZMA® and what does it treat?
AVTOZMA® is a biosimilar to ACTEMRA® used to treat several conditions such as rheumatoid arthritis, giant cell arteritis, juvenile arthritis, and COVID-19.
How does the FDA's approval benefit patients?
The approval enables greater access to treatments with proven efficacy, providing healthcare providers with effective alternatives to existing therapies.
What are the formulations available for AVTOZMA®?
AVTOZMA® is available in both intravenous and subcutaneous formulations, ensuring flexibility in administration for patients.
What clinical data supported AVTOZMA's FDA approval?
A phase III study demonstrated AVTOZMA's biosimilarity to tocilizumab, showing no significant differences in efficacy and safety.
What should patients be aware of regarding safety?
Patients should be monitored for serious infections, particularly if they are using other immunosuppressive medications while on AVTOZMA®.
